Access cutting-edge graft versus host disease treatment through this clinical trial at a research site in Omaha. Study-provided care at no cost to qualified participants.
Access graft versus host disease specialists in Omaha at no cost
This study follows strict safety protocols and ethical guidelines
All study-related graft versus host disease treatment provided free
This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive
Sponsor: Cynata Therapeutics Limited
Check if you qualify for this graft versus host disease clinical trial in Omaha, NE
If you're searching for graft versus host disease treatment options in Omaha, NE, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Omaha research site is actively enrolling participants for this clinical trial. You'll receive care from experienced graft versus host disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.